Date: 2017-06-29
Type of information: Research agreement
Compound: allogenic CAR-T cell therapies
Company: Servier (France) Transgene (France)
Therapeutic area:
Type agreement: research - R&D
Action mechanism: cell therapy/immunotherapy product/gene therapy/CAR-T cell therapy.
Disease:
Details:
- • On June 29, 2017, Servier and Transgene announced the signature of a research agreement on the application of viral vectorization technology for the production of allogenic CAR-T cell therapies. The aim is to obtain more efficient products for patients.
- The aim of the collaboration between the scientific teams at both Servier and Transgene is to evaluate and select innovative vectorization methods based on Transgene’s viral vector collection, which may be applied to the engineering of CAR-T cell therapies. In addition to the development of simpler, faster and more effective methods, the aim is also to obtain a tighter control of the modified genome areas. Servier and Transgene thus aim to achieve an original allogenic CAR-T preparation method with better transgene integration yields and fewer steps.
- Servier has been engaged in the development of cell therapies since November 2015, the company has exercised its worldwide option to license UCART19 under a strategic collaboration signed with Cellectis in November 2014.
Financial terms:
- Transgene may receive more than € 30 million for this contract, with an initial duration of three years.
Latest news:
Is general: Yes
